Sub-chronic administration of (−)-3-PPP and central dopamine receptor sensitivity changes
The effects of sub-chronic treatment with (−)-3-PPP (8 mg/kg, s.c., b.i.d. for 21 days), a dopaminergic agent with mixed agonist/antagonist properties, were investigated by means of behavioural andin vivo biochemical methods. There was no change in basal locomotor activity and central dopamine (DA) synthesis after 24 hours withdrawal. A slight, though significant reduction of the locomotor suppressive effect and of the DA synthesis-stimulating effect of acute (−)-3-PPP challenge doses of 0.125 and 1.0 mg/kg (s.c.), respectively, were demonstrated in (−)-3-PPP-pretreated as compared to vehicle-pretreated rats. No change in either action was evident after acute challenge with 8.0 mg/kg (s.c.) of the drug. The plasma levels of (−)-3-PPP were virtually unchanged by pretreatment with active drug. The findings are discussed in terms of a modest down- and up-regulation of DA autoreceptors and postsynaptic receptors, respectively, induced by the subchronic (−)-3-PPP treatment.
Key words(−)-3-PPP([−]-3-[3-hydroxyphenyl]-N-n-propylpiperidine) subchronic treatment rats dopamine receptors sensitivity changes
Unable to display preview. Download preview PDF.
- Ariens, E. J.: Receptors: the materialization of a concept. Pharmaceut. Weekbl. Sci. Ed.5, 121–128 (1983).Google Scholar
- Arnt, J., Bøgesø, K. P., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Dopamine receptor agonistic and antagonistic effects of 3-PPP enantiomers. Psychopharmacol.81, 199–207 (1983 a).Google Scholar
- Arnt, J., Christensen, A. V., Hyttel, J., Larsen, J.-J., Svendsen, O.: Effects of putative dopamine autoreceptor agonists in pharmacological models related to dopaminergic and neuroleptic activity. Eur. J. Pharmacol.86, 185–198 (1983 b).Google Scholar
- Hjorth, S.: On the mode of action of 3-(3-hydroxyphenyl)-N-n-propylpiperidine, 3-PPP, and its enantiomers. (Thesis) Acta Physiol. Scand.118, suppl. 517, 1–52 (1983).Google Scholar
- Hjorth, S., Carlsson, A., Clark, D., Svensson, K., Wikström, H., Sanchez, D., Lindberg, P., Hacksell, U., Arvidsson, L.-E., Johansson, A., Nilsson, J. L. G.: Central dopamine receptor agonist and antagonist actions of the enantiomers of 3-PPP. Psychopharmacol.81, 89–99 (1983).Google Scholar
- Kinon, B. J., Merson, D., Kane, J. M.: Effect of daily dose of chronic haloperidol and chronic apomorphine on behavioural hypersensitivity in the rat. Psychopharmacol.84, 347–350 (1984).Google Scholar
- Møller Nielsen, I., Christensen, A. V., Hyttel, J.: Adaptational phenomena in neuroleptic treatment. In: Adv. Biochem. Psychopharmacol., Vol. 19 (Roberts, P. J. et al., eds.), pp. 267–274. New York: Raven Press. 1978.Google Scholar
- Schwartz, J. C., Costentin, J., Martres, M. P., Protais, P., Baudry, M.: Modulation of receptor mechanisms in the CNS: hyper- and hyposensitivity to catecholamines. Neuropharmacol.17, 665–685 (1978).Google Scholar
- Shum, A., Sole, M. J., van Loon, G. R.: Simultaneous measurements of 5-hydroxytryptophan and L-dihydroxyphenylalanine by high-performance liquid chromatography with electrochemical detection. Measurement of serotonin and catecholamine turnover in discrete brain regions. J. Chromatogr.228, 123–130 (1982).PubMedGoogle Scholar
- Tarsy, D., Baldessarini, R. J.: Behavioural supersensitivity to apomorphine following chronic treatment with drugs which interfere with the synaptic function of catecholamines. Neuropharmacol.13, 927–940 (1974).Google Scholar